CommercialCoverageLow impact
08.02.24, Atidarsagene autotemcel (Lenmeldy)
Independence Blue Cross·Neurology, Pediatrics, Oncology·Medical Policy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
A new medical policy for Atidarsagene autotemcel (Lenmeldy) has been issued for commercial plans. This is a gene therapy treatment policy that will be reissued with an effective date of May 28, 2025.
Action Required
By May 28, 2025: Monitor for detailed policy guidelines regarding Atidarsagene autotemcel (Lenmeldy) coverage criteria and billing requirements. This gene therapy may require specific prior authorization processes and documentation when the full policy details are released.